Navigation Links
Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Date:4/15/2008

Biosciences, of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We are also investigating RDEA806 for the treatment of gout. Our lead MEK inhibitor, RDEA119, is in Phase 1 studies in advanced cancer patients and healthy volunteers for assessment as a treatment of inflammatory diseases. RDEA436, our second generation MEK inhibitor for the treatment of cancer and inflammatory diseases, has been evaluated in human micro-dose pharmacokinetic studies and selected as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
(Date:7/25/2014)... July 25, 2014 Leading events organizer ... returning for the seventh year to São Paulo, ... August 2014. The event will co-locate with Food Ingredients ... most comprehensive meeting point for the pharmaceutical industry. ... countries for pharmaceutical sales are now exploring the ...
(Date:7/24/2014)... Calif. , July 24, 2014   AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today confirmed the PDUFA date for Zalviso remains ... that a rumor circulated online stating the Food and ... 24, 2014 there has been no notification to the ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... Reportlinker.com announces that a new market ... Fetal Monitoring, Diagnostics and ... An overview of the ... tests. Analysis of market trends, with data ...
... -- Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the ... Traditional Chinese Medicine ("TCM") consumer products, today announced that ... conference call on Monday, May 16, 2011 at 8:00 ... the public pre-market on Monday, May 16, 2011. ...
Cached Medicine Technology:Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 2Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 3Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 4Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 5Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 6Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 7Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 8Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 9Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 10Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 11Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 2Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 3
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... 26, 2014 “Today, we introduce our ... clients all over the world. All these models are ... designed for the UK market,” says the CEO of ... suppliers of women’s special occasion outfits. , Ladies have ... comes. DressesOnlineShops.co.uk is one of the best choices for ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides ... report provides value, in millions of US dollars, volume ... market segments – Rigid Non-Video Sinuscopes. , The report ... each of these market categories, and global corporate-level profiles ... and deals related to the Sinuscopes market wherever available. ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York, New York (PRWEB) July 26, 2014 ... continue to be filed in U.S. courts, Bernstein ... calling on federal health regulators to ban uterine morcellation. ... individuals include a 46-year-old mother of four from California ... of uterine cancer called leiomyosarcoma just 10 days after ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... Inc. (Nasdaq: ISTA ), today announced it has ... that the Dermatologic and Ophthalmic Drugs Advisory Committee will review ... on June 26, 2009. , , On November 13, ... FDA for Bepreve as an eye drop treatment for ocular ...
... increase collaboration and resource-sharing in global PD scientific community ... The Michael J. Fox Foundation for Parkinson,s Research announced ... a resource-rich virtual workplace that MJFF hopes will become ... collaborating and conversing across the globe. MJFF,s goal in ...
... by any other name is still a rose, but ... ,athlete, and ,jock, are sometimes used interchangeably, but they ... University at Buffalo researcher Kathleen E. Miller, Ph.D. "In ... gender norms, these two identities represent very different perspectives ...
... Aon Affinity , a subsidiary of Aon Corporation ... Organization has launched the NSO Marketplace(SM) to offer ... insurance, risk management, professional and personal needs of the nursing community. For ... professional liability insurance to over 675,000 nurses in the ...
... method could boost survival, German study shows , ... approach to performing radical hysterectomy in early-stage cervical ... and local tumor recurrence, a German study shows. ... is a modified version of traditional radical hysterectomy. ...
... , Complimentary Continuing Education Lectures for Healthcare Professionals , ... is a challenging diagnosis which carries a poor prognosis ... several critical signaling and tumor suppressor pathways. While current ... improving outcomes for patients. In order to do this, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 2Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 3Health News:Don't mistake an athlete for a 'toxic jock' 2Health News:Exclusive Marketplace for Nursing Professionals Launched by Nurses Service Organization 2Health News:Exclusive Marketplace for Nursing Professionals Launched by Nurses Service Organization 3Health News:Adult Glioblastoma: Best Approaches to a Challenging Diagnosis 2
These claw forceps are single-action with sturdy teeth that provide a broad grasping area to hold the gallbladder securely during removal....
This is a single-action instrument that features a spring handle....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: